{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T19:23:54Z","timestamp":1793820234274,"version":"4.6.1"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2024,1,23]],"date-time":"2024-01-23T00:00:00Z","timestamp":1705968000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,1,23]],"date-time":"2024-01-23T00:00:00Z","timestamp":1705968000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Clin Dermatol"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1007\/s40257-024-00846-3","type":"journal-article","created":{"date-parts":[[2024,1,23]],"date-time":"2024-01-23T14:02:22Z","timestamp":1706018542000},"page":"299-314","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":63,"title":["Integrated Safety Analysis of Ritlecitinib, an Oral JAK3\/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial Program"],"prefix":"10.1007","volume":"25","clinical-trial-number":[{"clinical-trial-number":"nct02974868","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04517864","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03732807","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04006457","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Brett","family":"King","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Soung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christos","family":"Tziotzios","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lidia","family":"Rudnicka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascal","family":"Joly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melinda","family":"Gooderham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodney","family":"Sinclair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natasha A.","family":"Mesinkovska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carle","family":"Paul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yankun","family":"Gong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan D.","family":"Anway","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Tran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Wolk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel H.","family":"Zwillich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre","family":"Lejeune","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,1,23]]},"reference":[{"issue":"2","key":"846_CR1","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.autrev.2014.10.014","volume":"14","author":"N Islam","year":"2015","unstructured":"Islam N, Leung PS, Huntley AC, Gershwin ME. The autoimmune basis of alopecia areata: a comprehensive review. Autoimmun Rev. 2015;14(2):81\u20139.","journal-title":"Autoimmun Rev"},{"issue":"2","key":"846_CR2","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1111\/ajd.12941","volume":"60","author":"WC Cranwell","year":"2019","unstructured":"Cranwell WC, Lai VW, Photiou L, et al. Treatment of alopecia areata: an Australian expert consensus statement. Australas J Dermatol. 2019;60(2):163\u201370.","journal-title":"Australas J Dermatol"},{"key":"846_CR3","doi-asserted-by":"crossref","unstructured":"Delamere FM, Sladden MM, Dobbins HM, Leonardi-Bee J. Interventions for alopecia areata. Cochrane Database Syst Rev. 2008; (2):CD004413.","DOI":"10.1002\/14651858.CD004413.pub2"},{"issue":"3","key":"846_CR4","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1016\/j.jaad.2019.08.032","volume":"82","author":"HH Lee","year":"2020","unstructured":"Lee HH, Gwillim E, Patel KR, et al. Epidemiology of alopecia areata, ophiasis, totalis, and universalis: a systematic review and meta-analysis. J Am Acad Dermatol. 2020;82(3):675\u201382.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"846_CR5","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1001\/jamadermatol.2022.6085","volume":"159","author":"S Lauron","year":"2023","unstructured":"Lauron S, Plasse C, Vaysset M, et al. Prevalence and odds of depressive and anxiety disorders and symptoms in children and adults with alopecia areata: a systematic review and meta-analysis. JAMA Dermatol. 2023;159(3):281\u20138.","journal-title":"JAMA Dermatol"},{"issue":"3","key":"846_CR6","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1016\/j.jaad.2018.01.048","volume":"79","author":"LY Liu","year":"2018","unstructured":"Liu LY, King BA, Craiglow BG. Alopecia areata is associated with impaired health-related quality of life: a survey of affected adults and children and their families. J Am Acad Dermatol. 2018;79(3):556-558.e551.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"846_CR7","doi-asserted-by":"publisher","first-page":"S62","DOI":"10.1016\/j.jisp.2020.05.007","volume":"20","author":"N Mesinkovska","year":"2020","unstructured":"Mesinkovska N, King B, Mirmirani P, Ko J, Cassella J. Burden of illness in alopecia areata: a cross-sectional online survey study. J Investig Dermatol Symp Proc. 2020;20(1):S62\u20138.","journal-title":"J Investig Dermatol Symp Proc"},{"issue":"3","key":"846_CR8","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1007\/s13555-021-00512-0","volume":"11","author":"A Mostaghimi","year":"2021","unstructured":"Mostaghimi A, Napatalung L, Sikirica V, et al. Patient perspectives of the social, emotional and functional impact of alopecia areata: a systematic literature review. Dermatol Ther (Heidelb). 2021;11(3):867\u201383.","journal-title":"Dermatol Ther (Heidelb)."},{"issue":"18","key":"846_CR9","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1056\/NEJMoa2110343","volume":"386","author":"B King","year":"2022","unstructured":"King B, Ohyama M, Kwon O, et al. Two phase 3 trials of baricitinib for alopecia areata. N Engl J Med. 2022;386(18):1687\u201399.","journal-title":"N Engl J Med"},{"issue":"10387","key":"846_CR10","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.1016\/S0140-6736(23)00222-2","volume":"401","author":"B King","year":"2023","unstructured":"King B, Zhang X, Harcha WG, et al. Efficacy and safety of ritlecitinib in adults and adolescents with alopecia areata: a randomised, double-blind, multicentre, phase 2b\u20133 trial. Lancet. 2023;401(10387):1518\u201329.","journal-title":"Lancet"},{"issue":"suppl 1","key":"846_CR11","doi-asserted-by":"publisher","first-page":"i34","DOI":"10.1093\/rheumatology\/key287","volume":"58","author":"M Harigai","year":"2019","unstructured":"Harigai M. Growing evidence of the safety of JAK inhibitors in patients with rheumatoid arthritis. Rheumatology (Oxford). 2019;58(suppl 1):i34\u201342.","journal-title":"Rheumatology (Oxford)"},{"key":"846_CR12","doi-asserted-by":"publisher","first-page":"1759720X2093605","DOI":"10.1177\/1759720X20936059","volume":"12","author":"F Sunzini","year":"2020","unstructured":"Sunzini F, McInnes I, Siebert S. JAK inhibitors and infections risk: focus on herpes zoster. Ther Adv Musculoskelet Dis. 2020;12:1759720X20936059.","journal-title":"Ther Adv Musculoskelet Dis"},{"issue":"5","key":"846_CR13","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1038\/nrrheum.2017.51","volume":"13","author":"KL Winthrop","year":"2017","unstructured":"Winthrop KL. The emerging safety profile of JAK inhibitors in rheumatic disease. Nat Rev Rheumatol. 2017;13(5):320.","journal-title":"Nat Rev Rheumatol"},{"issue":"5","key":"846_CR14","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1007\/s40257-021-00618-3","volume":"22","author":"EL Simpson","year":"2021","unstructured":"Simpson EL, Silverberg JI, Nosbaum A, et al. Integrated safety analysis of abrocitinib for the treatment of moderate-to-severe atopic dermatitis from the phase II and phase III clinical trial program. Am J Clin Dermatol. 2021;22(5):693\u2013707.","journal-title":"Am J Clin Dermatol"},{"issue":"1","key":"846_CR15","doi-asserted-by":"publisher","first-page":"e002735","DOI":"10.1136\/rmdopen-2022-002735","volume":"9","author":"GR Burmester","year":"2023","unstructured":"Burmester GR, Cohen SB, Winthrop KL, et al. Safety profile of upadacitinib over 15,000 patient-years across rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and atopic dermatitis. RMD Open. 2023;9(1):e002735.","journal-title":"RMD Open"},{"issue":"2","key":"846_CR16","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1111\/jdv.16948","volume":"35","author":"T Bieber","year":"2021","unstructured":"Bieber T, Thyssen JP, Reich K, et al. Pooled safety analysis of baricitinib in adult patients with atopic dermatitis from 8 randomized clinical trials. J Eur Acad Dermatol Venereol. 2021;35(2):476\u201385.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"2","key":"846_CR17","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/j.jaad.2021.03.050","volume":"85","author":"B King","year":"2021","unstructured":"King B, Guttman-Yassky E, Peeva E, et al. A phase 2a randomized, placebo-controlled study to evaluate the efficacy and safety of the oral Janus kinase inhibitors ritlecitinib and brepocitinib in alopecia areata: 24-week results. J Am Acad Dermatol. 2021;85(2):379\u201387.","journal-title":"J Am Acad Dermatol"},{"key":"846_CR18","unstructured":"ICH Harmonised Tripartite Guideline: Clinical Safety Data Management: Definitions and Standards for Expedited Reporting E2A.\u00a0International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. Updated October 24, 1994."},{"issue":"3","key":"846_CR19","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1007\/s40257-021-00602-x","volume":"22","author":"B King","year":"2021","unstructured":"King B, Maari C, Lain E, et al. Extended safety analysis of baricitinib 2 mg in adult patients with atopic dermatitis: an integrated analysis from eight randomized clinical trials. Am J Clin Dermatol. 2021;22(3):395\u2013405.","journal-title":"Am J Clin Dermatol"},{"issue":"1","key":"846_CR20","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1182\/hematology.2020000118","volume":"2020","author":"A Lipsky","year":"2020","unstructured":"Lipsky A, Lamanna N. Managing toxicities of Bruton tyrosine kinase inhibitors. Hematol Am Soc Hematol Educ Program. 2020;2020(1):336\u201345.","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"846_CR21","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.720704","volume":"11","author":"SM O'Brien","year":"2021","unstructured":"O\u2019Brien SM, Brown JR, Byrd JC, et al. Monitoring and managing BTK inhibitor treatment-related adverse events in clinical practice. Front Oncol. 2021;11: 720704.","journal-title":"Front Oncol"},{"issue":"4","key":"846_CR22","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1111\/ejh.13020","volume":"100","author":"BF Tillman","year":"2018","unstructured":"Tillman BF, Pauff JM, Satyanarayana G, Talbott M, Warner JL. Systematic review of infectious events with the Bruton tyrosine kinase inhibitor ibrutinib in the treatment of hematologic malignancies. Eur J Haematol. 2018;100(4):325\u201334.","journal-title":"Eur J Haematol"},{"issue":"8","key":"846_CR23","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.1007\/s13555-023-00937-9","volume":"13","author":"P George","year":"2023","unstructured":"George P, Jagun O, Liu Q, et al. Incidence rates of infections, malignancies, thromboembolism, and cardiovascular events in an alopecia areata cohort from a US claims database. Dermatol Ther (Heidelb). 2023;13(8):1733\u201346.","journal-title":"Dermatol Ther (Heidelb)."},{"issue":"2","key":"846_CR24","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1093\/bjd\/ljac059","volume":"188","author":"B King","year":"2023","unstructured":"King B, Mostaghimi A, Shimomura Y, et al. Integrated safety analysis of baricitinib in adults with severe alopecia areata from two randomized clinical trials. Br J Dermatol. 2023;188(2):218\u201327.","journal-title":"Br J Dermatol"},{"key":"846_CR25","unstructured":"Olumiant (baricitinib). Prescribing Information. 2022. https:\/\/pi.lilly.com\/us\/olumiant-uspi.pdf. Accessed 9 Nov 2022."},{"key":"846_CR26","unstructured":"Rinvoq (upadacitinib). Prescribing information. 2022. https:\/\/www.rxabbviecom\/pdf\/rinvoq_pipdf. Accessed 22 Mar 2022."},{"key":"846_CR27","unstructured":"Sotyktu (deucravacitinib). Prescribing information. 2022. https:\/\/packageinserts.bms.com\/pi\/pi_sotyktu.pdf. Accessed 4 Dec 2023."},{"key":"846_CR28","unstructured":"Cinbinqo (abroctinib). Prescribing information. 2023. https:\/\/labeling.pfizer.com\/ShowLabeling.aspx?id=16652. Accessed 4 Dec 2023."},{"issue":"9","key":"846_CR29","doi-asserted-by":"publisher","first-page":"1861","DOI":"10.1007\/s00011-023-01789-x","volume":"72","author":"C Sun","year":"2023","unstructured":"Sun C, Su Z, Zeng YP. Association of risk of incident acne and treatment with systemic Janus kinase inhibitors in atopic dermatitis: a systematic review and meta-analysis. Inflamm Res. 2023;72(9):1861\u201371.","journal-title":"Inflamm Res"},{"issue":"12","key":"846_CR30","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1001\/jamadermatol.2023.3830","volume":"159","author":"J Martinez","year":"2023","unstructured":"Martinez J, Manjaly C, Manjaly P, et al. Janus kinase inhibitors and adverse events of acne: a systematic review and meta-analysis. JAMA Dermatol. 2023;159(12):1339\u201345.","journal-title":"JAMA Dermatol"},{"issue":"1","key":"846_CR31","doi-asserted-by":"publisher","DOI":"10.1111\/dth.14563","volume":"34","author":"SM Awad","year":"2021","unstructured":"Awad SM, Tawfik YM, El-Mokhtar MA, El-Gazzar AF, Abdel Motaleb AA. Activation of Janus kinase signaling pathway in acne lesions. Dermatol Ther. 2021;34(1): e14563.","journal-title":"Dermatol Ther"},{"issue":"1","key":"846_CR32","doi-asserted-by":"publisher","first-page":"2161812","DOI":"10.1080\/09546634.2022.2161812","volume":"34","author":"T Bieber","year":"2023","unstructured":"Bieber T, Katoh N, Simpson EL, et al. Safety of baricitinib for the treatment of atopic dermatitis over a median of 1.6 years and up to 3.9 years of treatment: an updated integrated analysis of eight clinical trials. J Dermatol Treat. 2023;34(1):2161812.","journal-title":"J Dermatol Treat"},{"issue":"4","key":"846_CR33","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1007\/s40257-023-00792-6","volume":"24","author":"L Stein Gold","year":"2023","unstructured":"Stein Gold L, Tha\u00e7i D, Thyssen JP, et al. Safety of lebrikizumab in adults and adolescents with moderate-to-severe atopic dermatitis: an integrated analysis of eight clinical trials. Am J Clin Dermatol. 2023;24(4):595\u2013607.","journal-title":"Am J Clin Dermatol"},{"issue":"1","key":"846_CR34","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.jaci.2022.09.023","volume":"151","author":"E Guttman-Yassky","year":"2023","unstructured":"Guttman-Yassky E, Thyssen JP, Silverberg JI, et al. Safety of upadacitinib in moderate-to-severe atopic dermatitis: an integrated analysis of phase 3 studies. J Allergy Clin Immunol. 2023;151(1):172\u201381.","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"846_CR35","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1056\/NEJMoa2109927","volume":"386","author":"SR Ytterberg","year":"2022","unstructured":"Ytterberg SR, Bhatt DL, Mikuls TR, et al. Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis. N Engl J Med. 2022;386(4):316\u201326.","journal-title":"N Engl J Med"},{"issue":"4","key":"846_CR36","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1007\/s40264-017-0622-2","volume":"41","author":"A Verden","year":"2018","unstructured":"Verden A, Dimbil M, Kyle R, Overstreet B, Hoffman KB. Analysis of spontaneous postmarket case reports submitted to the FDA regarding thromboembolic adverse events and JAK inhibitors. Drug Saf. 2018;41(4):357\u201361.","journal-title":"Drug Saf"},{"key":"846_CR37","unstructured":"US Food and Drug Administration. FDA requires warnings about increased risk of serious heart-related events, cancer, blood clots, and death for JAK inhibitors that treat certain chronic inflammatory conditions. 2021. https:\/\/www.fda.gov\/media\/151936\/download."},{"issue":"11","key":"846_CR38","doi-asserted-by":"publisher","first-page":"4910","DOI":"10.1007\/s12325-022-02281-4","volume":"39","author":"T Bieber","year":"2022","unstructured":"Bieber T, Feist E, Irvine AD, et al. A review of safety outcomes from clinical trials of baricitinib in rheumatology, dermatology and COVID-19. Adv Ther. 2022;39(11):4910\u201360.","journal-title":"Adv Ther"},{"issue":"6","key":"846_CR39","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1007\/s40257-023-00805-4","volume":"24","author":"S Ly","year":"2023","unstructured":"Ly S, Manjaly P, Kamal K, Shields A, et al. Comorbid conditions associated with alopecia areata: a systematic review and meta-analysis. Am J Clin Dermatol. 2023;24(6):875\u201393.","journal-title":"Am J Clin Dermatol"},{"issue":"10","key":"846_CR40","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1002\/acr.23930","volume":"71","author":"DD Gladman","year":"2019","unstructured":"Gladman DD, Charles-Schoeman C, McInnes IB, et al. Changes in lipid levels and incidence of cardiovascular events following tofacitinib treatment in patients with psoriatic arthritis: a pooled analysis across phase III and long-term extension studies. Arthritis Care Res (Hoboken). 2019;71(10):1387\u201395.","journal-title":"Arthritis Care Res (Hoboken)."},{"issue":"7","key":"846_CR41","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a002287","volume":"2","author":"AH Andreotti","year":"2010","unstructured":"Andreotti AH, Schwartzberg PL, Joseph RE, Berg LJ. T-cell signaling regulated by the Tec family kinase, Itk. Cold Spring Harb Perspect Biol. 2010;2(7):a002287.","journal-title":"Cold Spring Harb Perspect Biol"},{"issue":"11","key":"846_CR42","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1016\/j.molimm.2010.12.007","volume":"48","author":"T Kurosaki","year":"2011","unstructured":"Kurosaki T. Regulation of BCR signaling. Mol Immunol. 2011;48(11):1287\u201391.","journal-title":"Mol Immunol"},{"key":"846_CR43","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.630942","volume":"9","author":"HY Estupi\u00f1\u00e1n","year":"2021","unstructured":"Estupi\u00f1\u00e1n HY, Bergl\u00f6f A, Zain R, Smith CIE. Comparative analysis of BTK inhibitors and mechanisms underlying adverse effects. Front Cell Dev Biol. 2021;9:630942.","journal-title":"Front Cell Dev Biol"}],"updated-by":[{"DOI":"10.1007\/s40257-024-00864-1","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2024,5,24]],"date-time":"2024-05-24T00:00:00Z","timestamp":1716508800000}},{"DOI":"10.1007\/s40257-025-00976-2","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T00:00:00Z","timestamp":1757548800000}},{"DOI":"10.1007\/s40257-026-01051-0","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T00:00:00Z","timestamp":1781740800000}},{"DOI":"10.1007\/s40257-026-01070-x","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T00:00:00Z","timestamp":1790294400000}}],"container-title":["American Journal of Clinical Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-024-00846-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40257-024-00846-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-024-00846-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T03:20:35Z","timestamp":1790306435000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40257-024-00846-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,23]]},"references-count":43,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["846"],"URL":"https:\/\/doi.org\/10.1007\/s40257-024-00846-3","relation":{},"ISSN":["1175-0561","1179-1888"],"issn-type":[{"value":"1175-0561","type":"print"},{"value":"1179-1888","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,23]]},"assertion":[{"value":"16 January 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 January 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 September 2026","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original online version of this article was revised due to update in the text","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 May 2024","order":7,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":8,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":9,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s40257-024-00864-1","URL":"https:\/\/doi.org\/10.1007\/s40257-024-00864-1","order":10,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 June 2026","order":11,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":12,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":13,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s40257-026-01051-0","URL":"https:\/\/doi.org\/10.1007\/s40257-026-01051-0","order":14,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 September 2025","order":15,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":16,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":17,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s40257-025-00976-2","URL":"https:\/\/doi.org\/10.1007\/s40257-025-00976-2","order":18,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 September 2026","order":19,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":20,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":21,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s40257-026-01070-x","URL":"https:\/\/doi.org\/10.1007\/s40257-026-01070-x","order":22,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was sponsored by Pfizer Inc.","order":1,"name":"Ethics","label":"Funding","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Brett King: AbbVie, AltruBio, Almirall, AnaptysBio, Arena Pharmaceuticals, Bioniz Therapeutics, Bristol Myers Squibb, Concert Pharmaceuticals, Equillium, Horizon Therapeutics, Eli Lilly, Incyte, Janssen Pharmaceuticals, LEO Pharma, Otsuka\/Visterra, Pfizer, Regeneron, Sanofi Genzyme, TWi Biotechnology, and Viela Bio. He has served on speaker bureaus for Pfizer. Jennifer Soung: speaker for Regeneron\/Sanofi and Ortho Dermatologics; speaker and investigator for Amgen, AbbVie, and Pfizer; speaker, investigator, and advisor for Eli Lilly; investigator and advisor for LEO Pharma; investigator, speaker, and consultant for Novartis; investigator for UCB, Janssen, Kyowa Kirin, KoBio Labs, and Castel Biosciences; investigator and consultant for Dermavant; speaker and consultant for Bristol Myers Squibb, speaker, investigator and consultant for Arcutis. Christos Tziotzios: speaker for LEO Pharma; principal and chief investigator for Pfizer; consultant for Pfizer. Lidia Rudnicka: speaker for AbbVie, L'Oreal, LEO Pharma, Novartis, Pierre Fabre, and Pfizer; advisory board member for LEO Pharma, Janssen, L'Oreal, Novartis, Pfizer, Sanofi, and UCB. Pascal Joly: consultant for Amgen, Argenx, AstraZeneca, Innovaderm, Principia Biopharma, Roche, Sanofi-Regeneron Pharmaceuticals, Thermo Fisher Scientific, Novartis, Pfizer, Lilly, AbbVie, and Janssen Cilag. Melinda Gooderham: investigator, speaker, and\/or advisor for AbbVie, Amgen, Akros, AnaptysBio, Arcutis, Bausch Health, Bristol Myers Squibb, Boehringer Ingelheim, Celgene, Dermira, Dermavant, Eli Lilly, Galderma, GSK, Incyte, Janssen, Kyowa Kirin, LEO Pharma, MedImmune, Merck, Moonlake, Nimbus, Novartis, Pfizer, Regeneron, Reistone, Roche, Sanofi Genzyme, Sun Pharma, and UCB. Rodney Sinclair: professional services to Aerotech, AbbVie, AstraZeneca, Akesobio, Amgen, Arcutis, Arena, Ascend, Bayer, Bristol Myers Squibb, Boehringer Ingelheim, Celgene, Coherus Biosciences, Connect, Cutanea, Demira, Eli Lilly, Galderma, GSK, Janssen, LEO Pharma, MedImmune, Merck, MSD, Novartis, Oncobiologics, Pfizer, Regeneron, Reistone, Roche, Samson Clinical, Sanofi, Sun Pharma, and UCB. Natasha A. Mesinkovska: professional services to AbbVie, Arena Pharmaceuticals, Bristol Myers Squibb, Concert Pharmaceuticals, Eli Lilly, La Roche Posay, and Pfizer. Carle Paul: consulting fees and\/or grants from AbbVie, Almirall, Amgen, Boehringer Ingelheim, Celgene, GSK, Janssen Cilag, LEO Pharma, Eli Lilly, Novartis, Pierre Fabre, Pfizer, Sanofi, and UCB Pharma. Yankun Gong, Helen Tran, Robert Wolk, Samuel H. Zwillich, and Alexandre Lejeune are employees of, and hold stock or stock options in, Pfizer. Susan D. Anway was an employee of Pfizer at the time of the study and holds stock or stock options in Pfizer.","order":2,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Upon request and subject to review, Pfizer will provide the data that support the findings of this study. Subject to certain criteria, conditions, and exceptions, Pfizer may also provide access to the related individual de-identified participant data. See\n                      \n                      for more information.","order":3,"name":"Ethics","label":"Data availability","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethics approval was obtained for individual studies included in this integrated safety analysis. The study was performed in accordance with the ethical standards as provided in the Declaration of Helsinki.","order":4,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Informed consent was obtained from all participants of the individual studies included in this integrated safety analysis.","order":5,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Patients signed informed consent regarding publishing their data.","order":6,"name":"Ethics","label":"Patient consent to publish","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":7,"name":"Ethics","label":"Code availability","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors contributed to the concept and design of the study, to data analysis and interpretation, to critical revision of the publication, and all authors read and approved the final manuscript.","order":8,"name":"Ethics","label":"Author contributions","group":{"name":"EthicsHeading","label":"Declarations"}}]}}